Literature DB >> 34033059

MOG antibody-associated disease presenting with tumefactive lesions and closed-ring enhancement.

Yin-Xi Zhang1, Yang Zheng1, Meng-Ting Cai1, Qiang Du1, Mei-Ping Ding2.   

Abstract

Entities:  

Keywords:  Closed-ring enhancement; Myelin oligodendrocyte glycoprotein antibody; Tumefactive demyelinating lesion

Mesh：

Substances：

Year:  2021        PMID： 34033059     DOI： 10.1007/s13760-021-01695-1

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN： 0300-9009            Impact factor:   2.396


× No keyword cloud information.
  5 in total

Review 1.  MRI features of demyelinating disease associated with anti-MOG antibodies in adults.

Authors:  Marc Denève; Damien Biotti; Sofia Patsoura; Marine Ferrier; Zuzana Meluchova; Laurence Mahieu; Françoise Heran; Catherine Vignal; Romain Deschamps; Olivier Gout; Nicolas Menjot de Champfleur; Xavier Ayrignac; Clarisse Carra Dallière; Pierre Labauge; Cécile Dulau; Thomas Tourdias; Hervé Dumas; Christophe Cognard; David Brassat; Fabrice Bonneville
Journal:  J Neuroradiol       Date:  2019-06-20       Impact factor: 3.447

Review 2.  Pseudotumoral demyelinating lesions: diagnostic approach and long-term outcome.

Authors:  Todd A Hardy
Journal:  Curr Opin Neurol       Date:  2019-06       Impact factor: 5.710

3.  Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.

Authors:  Maciej Jurynczyk; Ruth Geraldes; Fay Probert; Mark R Woodhall; Patrick Waters; George Tackley; Gabriele DeLuca; Saleel Chandratre; Maria I Leite; Angela Vincent; Jacqueline Palace
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

4.  Open-ring imaging sign: highly specific for atypical brain demyelination.

Authors:  J C Masdeu; C Quinto; C Olivera; M Tenner; D Leslie; P Visintainer
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

Review 5.  Race and hypertension. What is clinically relevant?

Authors:  D R Rutledge
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.